(Alliance News) - Cizzle Biotechnology PLC and Vela Technologies PLC on Tuesday noted that blank-check special purpose acquisition company Murphy Canyon Acquisition Corp will hold a special meeting on September 7. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Cizzle Biotechnology Holdings PLC said on Monday that it raised GBP350,000 from a subscription of 16.7 million shares at 2.1 pence per share, with new and existing investors. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Cizzle Biotechnology Holdings PLC said on Monday it signed a new 12-month agreement with the University of York for the development of a cancer diagnosis technology. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Signs further Memorandum of Understanding with International Co-Innovation Centre for Advanced Medical Technology for a clinical pilot study with the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Center of China. The clinical pilot study will evaluate optimised assays using a monoclonal antibody that Cizzle Biotechnology has developed that specifically detects CIZ1B, which is highly associated with stage 1 lung cancer. Read More
Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - and Vela Technologies PLC - Bradford, England-based investment firm focused on early-stage and pre-IPO disruptive technology investments - Notes announcement by Conduit Pharmaceuticals Ltd that it intends to become a publicly traded company on the Nasdaq in the US through a merger with special purpose acquisition firm Murphy Cannon Acquisition Corp. The deal is expected to generate USD149.7 million worth of proceeds for Conduit. Read More
(Alliance News) - Cizzle Biotechnology Holdings PLC on Wednesday said it had passed "key milestones" as it moved towards generating revenue for its products. Read More
(Alliance News) - Vela Technologies PLC and Cizzle Biotechnology Holdings PLC on Thursday hailed the latest clinical trial results from investee St George Street Capital Ltd. Read More
(Alliance News) - Cizzle Biotechnology Holdings PLC on Tuesday said that it is using its early-stage lung cancer test technology to detect more cancer types, notably breast cancer. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Posts higher annual loss in 2021. Pretax loss widens to GBP4.0 million from GBP14,000 in 2020. In May 2021, Cizzle was bought by Bould Opportunities PLC. Acquisition-related costs stand at GBP3.1 million in 2021 versus none in 2020. Read More
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday. Read More
(Alliance News) - Cizzle Biotechnology Holdings PLC on Friday announced a new collaboration into lung cancer testing with a US partner. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Reports that Arcadia clinical study shows potential value of AZD1656 treatment for Covid-19 patients. The new data analysis comes from St George Street Capital Ltd, which runs the trial with Excalibur Medicines Ltd for the treatment, in which Cizzle holds a "significant" royalty-bearing economic interest. Read More